Update shared on 14 Dec 2025
Analysts have modestly reaffirmed their outlook on Labcorp Holdings, maintaining the price target effectively unchanged at approximately $300 per share. They continue to see a stable balance of revenue growth, profit margins, and valuation multiples.
What's in the News
- Labcorp Plasma Detect, a tumor-informed blood test for molecular residual disease, was featured in Nature Medicine and Clinical Cancer Research, with studies showing its potential to track early disease progression and predict long term survival in diffuse pleural mesothelioma and to improve post surgical monitoring in head and neck cancer (peer reviewed journals).
- Labcorp and Lunit launched a collaboration to apply AI driven digital pathology to oncology research and clinical care, using whole slide imaging and spatial profiling to better characterize tumor immune microenvironments and refine precision immuno oncology strategies (company announcement).
- Labcorp lowered its full year 2025 revenue growth guidance to a range of 7.4% to 8.0%, down from the prior 7.5% to 8.6%. This signals a slightly more cautious outlook on top line expansion (company guidance).
- The company completed a tranche of its share repurchase program, buying back 100,000 shares in the third quarter of 2025 and reaching a total of about 16% of shares retired since the buyback was announced in 2021 (company filing).
- Labcorp announced plans to offer Roche's FDA cleared Elecsys pTau181 blood test nationwide by early 2026, expanding access in primary care to a less invasive biomarker tool to help rule out Alzheimer's related amyloid pathology in older adults with cognitive decline (company announcement).
Valuation Changes
- Fair Value: Remains effectively unchanged at approximately $300 per share, indicating no material adjustment to intrinsic value estimates.
- Discount Rate: Edged down marginally from 6.956% to about 6.956%, reflecting an immaterial shift in the cost of capital assumption.
- Revenue Growth: Ticked down very slightly from 4.80% to about 4.80%, implying a virtually unchanged long term growth outlook.
- Net Profit Margin: Increased fractionally from roughly 8.55% to 8.55%, signaling a negligible uplift in expected profitability.
- Future P/E: Held steady at around 21.66x, suggesting no change in the valuation multiple applied to forward earnings.
Have other thoughts on Labcorp Holdings?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.